**S5 Table.** Conditional estimates and 95% credible intervals for lnRR and lnCVR, obtained from contrast multi-level regression (MLMR) models to assess the effect of sex on infarct volume. The intercept here represents studies in which “Both” sexes were used. Bold italicized estimates indicate that the 95% credible intervals do not span zero.

|  |  |  |
| --- | --- | --- |
| Parameters | lnRR | lnCVR |
| $$ β$$ | LCI | UCI | $$β$$ | LCI | UCI |
| Intercept | ***-0.511*** | ***-0.740*** | ***-0.282*** | 0.171 | -0.153 | 0.494 |
| Sex FEMALE | -0.125 | -0.352 | 0.103 | 0.154 | -0.174 | 0.482 |
| Sex MALE | -0.184 | -0.399 | 0.031 | ***0.318*** | ***0.013*** | ***0.623*** |
| DrugGroup ANGIOTENSIN RECEPTOR BLOCKER (ARB) | ***0.577*** | ***0.043*** | ***1.111*** | -0.164 | -1.048 | 0.720 |
| DrugGroup ANTI-INFLAMMATORY | 0.185 | -0.002 | 0.371 | -0.136 | -0.398 | 0.127 |
| DrugGroup ANTIBIOTIC | ***0.355*** | ***0.052*** | ***0.658*** | -0.250 | -0.654 | 0.155 |
| DrugGroup ANTIDEPRESSANT | ***0.402*** | ***0.230*** | ***0.574*** | -0.126 | -0.378 | 0.126 |
| DrugGroup ANTIOXIDANT | ***0.229*** | ***0.107*** | ***0.351*** | -0.131 | -0.311 | 0.048 |
| DrugGroup CITOCHOLINE | ***0.346*** | ***0.160*** | ***0.533*** | ***-0.528*** | ***-0.813*** | ***-0.244*** |
| DrugGroup ENVIRONMENT | ***0.758*** | ***0.517*** | ***0.998*** | ***-0.547*** | ***-0.899*** | ***-0.196*** |
| DrugGroup ESTROGEN | 0.152 | -0.023 | 0.326 | -0.121 | -0.375 | 0.133 |
| DrugGroup EXERCISE | ***0.365*** | ***0.215*** | ***0.514*** | ***-0.277*** | ***-0.491*** | ***-0.063*** |
| DrugGroup GROWTH FACTOR | ***0.327*** | ***0.214*** | ***0.439*** | ***-0.179*** | ***-0.345*** | ***-0.013*** |
| DrugGroup HBOT | ***0.589*** | ***0.050*** | ***1.128*** | ***-1.073*** | ***-1.958*** | ***-0.188*** |
| DrugGroup HMG-CoA REDUCTASE ANTAGONIST | ***0.327*** | ***0.183*** | ***0.471*** | -0.139 | -0.350 | 0.073 |
| DrugGroup IMMUNOSUPPRESSANT | ***0.210*** | ***0.062*** | ***0.358*** | -0.022 | -0.236 | 0.192 |
| DrugGroup MIXED TRAINING | ***0.678*** | ***0.420*** | ***0.935*** | ***-0.610*** | ***-0.995*** | ***-0.224*** |
| DrugGroup MK801 | ***0.288*** | ***0.140*** | ***0.435*** | -0.093 | -0.315 | 0.129 |
| DrugGroup NOOTROPIC | 0.163 | -0.185 | 0.511 | -0.193 | -0.677 | 0.291 |
| DrugGroup NO DONOR | ***0.430*** | ***0.260*** | ***0.600*** | -0.152 | -0.411 | 0.108 |
| DrugGroup NOS INHIBITOR | ***0.381*** | ***0.265*** | ***0.496*** | ***-0.281*** | ***-0.450*** | ***-0.111*** |
| DrugGroup OMEGA-3 | 0.056 | -0.088 | 0.201 | -0.068 | -0.275 | 0.138 |
| DrugGroup PPAR-GAMMA AGONIST | ***0.156*** | ***0.026*** | ***0.285*** | -0.175 | -0.371 | 0.022 |
| DrugGroup GTPase INHIBITOR | 0.140 | -0.055 | 0.336 | -0.077 | -0.358 | 0.205 |
| DrugGroup STEM CELLS | ***0.465*** | ***0.366*** | ***0.564*** | ***-0.274*** | ***-0.424*** | ***-0.125*** |
| DrugGroup THROMBOLYTICS | ***0.336*** | ***0.233*** | ***0.438*** | ***-0.310*** | ***-0.458*** | ***-0.162*** |
| DrugGroup TRAINING | ***0.735*** | ***0.442*** | ***1.028*** | ***-0.477*** | ***-0.877*** | ***-0.077*** |
| DrugGroup VITAMIN | ***0.265*** | ***0.061*** | ***0.468*** | -0.141 | -0.443 | 0.162 |